Solvay Luvox Resubmission Has February Deadline; Rowasa NDA Withdrawn
Executive Summary
FDA's user fee date for action on Solvay's application for re-approval of the obsessive compulsive disorder agent Luvox (fluvoxamine) is early February
You may also be interested in...
Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma
Solvay plans to continue working with Abbott on the Tricor franchise in the U.S. after acquiring Fournier Pharma
Solvay Picks Up Tricor Franchise Through Acquisition Of Fournier Pharma
Solvay plans to continue working with Abbott on the Tricor franchise in the U.S. after acquiring Fournier Pharma
Antidepressant Suicide Risk In Eight Drug Labels; Pfizer Is Hold-Out
Eight out of 10 antidepressant manufacturers asked by FDA to include a class warning in labeling on suicide risks have complied with the agency's request